Pliant Therapeutics shares were up 23% to $3.34 after the company said an independent Data Safety Monitoring Board is allowing it to begin the assembly of an outside expert panel to review unblinded ...

Pliant Therapeutics (NASDAQ:PLRX) stock, currently trading at $3.23, maintained a Buy rating and a $32.00 price target from Stifel analysts following recent developments in the company's clinical ...

Pliant Therapeutics shares fell sharply in pre-market trading Monday after it said it would pause its pulmonary fibrosis drug following a review by independent monitors. Shares traded 55% lower ahead ...

Pliant Therapeutics (PLRX) announced that following a prespecified data review and recommendations by the trial’s independent Data Safety ...

Pliant Therapeutics (NASDAQ:PLRX) stock plunged 61% in the wake of news that it has paused enrollment in a Phase 2b study of its drug bexotegrast in patients with idiopathic pulmonary fibrosis. Pliant ...

In contrast, patient safety indicators derived from administrative data reflect highly specific events or processes ... though can be complemented by locally developed measures. But day-to-day ...

The company's press release indicated that the enrollment and dosing for the BEACON-IPF trial were voluntarily paused to review data and understand the DSMB's recommendation. While the study remains ...

Lloyd’s Register Foundation has awarded £300,000 to the Engineers Board of Kenya to improve safety in the construction industry in Kenya ...

7 that the company has voluntarily paused enrollment and dosing in BEACON-IPF on the recommendation of the trial’s independent data safety monitoring board (DSMB). The advice followed a ...

today announced that the Data Safety Monitoring Committee (DSMC) has recently completed its second independent review of the ongoing ORCA-OL trial, evaluating long-term exposure of the novel 3 mg ...